CETRORELIX ACETATE Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Cetrorelix Acetate, and what generic alternatives are available?
Cetrorelix Acetate is a drug marketed by Gland, Livzon Grp, Qilu, and Teva Pharms Inc. and is included in four NDAs.
The generic ingredient in CETRORELIX ACETATE is cetrorelix acetate. There is one drug master file entry for this compound. Seven suppliers are listed for this compound. Additional details are available on the cetrorelix acetate profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Cetrorelix Acetate
A generic version of CETRORELIX ACETATE was approved as cetrorelix acetate by TEVA PHARMS INC on August 12th, 2022.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for CETRORELIX ACETATE?
- What are the global sales for CETRORELIX ACETATE?
- What is Average Wholesale Price for CETRORELIX ACETATE?
Summary for CETRORELIX ACETATE
| US Patents: | 0 |
| Applicants: | 4 |
| NDAs: | 4 |
| Finished Product Suppliers / Packagers: | 6 |
| Raw Ingredient (Bulk) Api Vendors: | 49 |
| Clinical Trials: | 23 |
| Patent Applications: | 4,456 |
| Drug Prices: | Drug price information for CETRORELIX ACETATE |
| DailyMed Link: | CETRORELIX ACETATE at DailyMed |
Recent Clinical Trials for CETRORELIX ACETATE
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Northwest Women's and Children's Hospital, Xi'an, Shaanxi | N/A |
| Bezmialem Vakif University | N/A |
| Bio Genuine (Shanghai) Biotech Co., Ltd. | Phase 2 |
Anatomical Therapeutic Chemical (ATC) Classes for CETRORELIX ACETATE
US Patents and Regulatory Information for CETRORELIX ACETATE
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gland | CETRORELIX ACETATE | cetrorelix acetate | POWDER;SUBCUTANEOUS | 218150-001 | Apr 25, 2024 | AP | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| Teva Pharms Inc | CETRORELIX ACETATE | cetrorelix acetate | POWDER;SUBCUTANEOUS | 215737-001 | Aug 12, 2022 | AP | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| Livzon Grp | CETRORELIX ACETATE | cetrorelix acetate | POWDER;SUBCUTANEOUS | 214540-001 | Apr 24, 2024 | AP | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| Qilu | CETRORELIX ACETATE | cetrorelix acetate | POWDER;SUBCUTANEOUS | 217776-001 | Apr 16, 2024 | AP | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
EU/EMA Drug Approvals for CETRORELIX ACETATE
| Company | Drugname | Inn | Product Number / Indication | Status | Generic | Biosimilar | Orphan | Marketing Authorisation | Marketing Refusal |
|---|---|---|---|---|---|---|---|---|---|
| Merck Europe B.V. | Cetrotide | cetrorelix | EMEA/H/C/000233 Prevention of premature ovulation in patients undergoing a controlled ovarian stimulation, followed by oocyte-pick-up and assisted-reproductive techniques.In clinical trials, Cetrotide was used with human menopausal gonadotropin (HMG), however, limited experience with recombinant follicule-stimulating hormone (FSH) suggested similar efficacy. |
Authorised | no | no | no | 1999-04-12 | |
| >Company | >Drugname | >Inn | >Product Number / Indication | >Status | >Generic | >Biosimilar | >Orphan | >Marketing Authorisation | >Marketing Refusal |
